MX2023002352A - Formulaciones de un inhibidor de mcl-1. - Google Patents
Formulaciones de un inhibidor de mcl-1.Info
- Publication number
- MX2023002352A MX2023002352A MX2023002352A MX2023002352A MX2023002352A MX 2023002352 A MX2023002352 A MX 2023002352A MX 2023002352 A MX2023002352 A MX 2023002352A MX 2023002352 A MX2023002352 A MX 2023002352A MX 2023002352 A MX2023002352 A MX 2023002352A
- Authority
- MX
- Mexico
- Prior art keywords
- mcl
- inhibitor formulations
- amg
- formulations
- inhibitor
- Prior art date
Links
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 title 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- BJTFTQIBRVBSBH-VCQPVEJUSA-N CO[C@]1(CN2CCN3CCCC[C@@H]3C2)\C=C\C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)C2=CC3=C(OC[C@]4(CCCC5=C4C=CC(Cl)=C5)CN3C[C@@H]3CC[C@@H]13)C=C2 Chemical compound CO[C@]1(CN2CCN3CCCC[C@@H]3C2)\C=C\C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)C2=CC3=C(OC[C@]4(CCCC5=C4C=CC(Cl)=C5)CN3C[C@@H]3CC[C@@H]13)C=C2 BJTFTQIBRVBSBH-VCQPVEJUSA-N 0.000 abstract 2
- 239000007962 solid dispersion Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
Abstract
En la presente se proporcionan dispersiones sólidas que comprenden AMG 397, métodos para preparar la dispersión sólida, y formulaciones farmacéuticas que comprenden AMG 397. (ver fórmula) ( AMG 397).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063070630P | 2020-08-26 | 2020-08-26 | |
| PCT/US2021/047237 WO2022046690A1 (en) | 2020-08-26 | 2021-08-24 | Mcl-1 inhibitor formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002352A true MX2023002352A (es) | 2023-04-14 |
Family
ID=77802255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002352A MX2023002352A (es) | 2020-08-26 | 2021-08-24 | Formulaciones de un inhibidor de mcl-1. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230312606A1 (es) |
| EP (1) | EP4203922A1 (es) |
| JP (2) | JP2022039996A (es) |
| CN (1) | CN116113473A (es) |
| AR (1) | AR123327A1 (es) |
| AU (1) | AU2021330948A1 (es) |
| CA (1) | CA3192624A1 (es) |
| MX (1) | MX2023002352A (es) |
| TW (1) | TW202222321A (es) |
| UY (1) | UY39393A (es) |
| WO (1) | WO2022046690A1 (es) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6453507B2 (ja) * | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
-
2021
- 2021-08-04 JP JP2021127983A patent/JP2022039996A/ja active Pending
- 2021-08-18 TW TW110130474A patent/TW202222321A/zh unknown
- 2021-08-23 UY UY0001039393A patent/UY39393A/es unknown
- 2021-08-23 AR ARP210102377A patent/AR123327A1/es unknown
- 2021-08-24 CN CN202180062139.7A patent/CN116113473A/zh active Pending
- 2021-08-24 JP JP2023513126A patent/JP2023539198A/ja active Pending
- 2021-08-24 CA CA3192624A patent/CA3192624A1/en active Pending
- 2021-08-24 AU AU2021330948A patent/AU2021330948A1/en active Pending
- 2021-08-24 EP EP21772900.3A patent/EP4203922A1/en active Pending
- 2021-08-24 MX MX2023002352A patent/MX2023002352A/es unknown
- 2021-08-24 US US18/022,905 patent/US20230312606A1/en active Pending
- 2021-08-24 WO PCT/US2021/047237 patent/WO2022046690A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR123327A1 (es) | 2022-11-23 |
| EP4203922A1 (en) | 2023-07-05 |
| UY39393A (es) | 2022-02-25 |
| JP2023539198A (ja) | 2023-09-13 |
| JP2022039996A (ja) | 2022-03-10 |
| AU2021330948A1 (en) | 2023-03-30 |
| CN116113473A (zh) | 2023-05-12 |
| TW202222321A (zh) | 2022-06-16 |
| CA3192624A1 (en) | 2022-03-03 |
| US20230312606A1 (en) | 2023-10-05 |
| WO2022046690A1 (en) | 2022-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023008031A (es) | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. | |
| MX2021009259A (es) | Conjugados de il-2 y metodos de uso del mismo. | |
| WO2020243415A3 (en) | Tead inhibitors and uses thereof | |
| WO2020016659A3 (en) | Multiparticulate formulations of cannabinoids | |
| MX2020007799A (es) | Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos. | |
| PH12018502438A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12019500202A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12019500208A1 (en) | Spiro-lactam nmda receptor modulators and methods of using same | |
| PH12019500207A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| PH12019500206A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| MY195500A (en) | Vesicles Derived From Lactobacillus Paracasei And Use Of Same | |
| MX2019001322A (es) | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos. | |
| MX2021006564A (es) | Sistemas activos dinamicos acromosomicos. | |
| PH12020551716A1 (en) | Anti-ror antibody constructs | |
| MX2021006674A (es) | Composiciones para estabilizar bacterias y usos de las mismas. | |
| EP4241769A3 (en) | Bisphosphocin gel formulations and uses thereof | |
| CR20220215A (es) | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 | |
| WO2018064472A8 (en) | FORMS OF SOLID DISPERSIONS OF RIFAXIMINE | |
| MX2020011756A (es) | Compuesto farmaceutico, sales del mismo, formulaciones del mismo y metodos para hacer y usar el mismo. | |
| PH12021550413A1 (en) | Vitamin d pediatric dosage forms, methods of making and using | |
| MX2022000712A (es) | Moduladores de nlrp3. | |
| MX2022006312A (es) | Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos. | |
| MX2023002352A (es) | Formulaciones de un inhibidor de mcl-1. | |
| MX2021005038A (es) | Dispersiones solidas y composiciones farmaceuticas que comprenden un indano sustituido y metodos para la preparacion y uso de las mismas. | |
| WO2019151964A3 (en) | Orally disintegrating formulations of saxagliptin |